# Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

Study · id `cardio:ct-nct04239391` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04239391](<https://clinicaltrials.gov/study/NCT04239391>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04239391

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT04239391. Randomized; no masking; primary purpose treatment. Start 2020-09-01 (actual); primary completion 2023-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT04239391, source copy `cardio:ctgov-nct04239391-2021-04-21`, retrieved 2026-10-26)
- Started: 2020-09-01 (actual) (ClinicalTrials.gov record NCT04239391, source copy `cardio:ctgov-nct04239391-2021-04-21`, retrieved 2026-10-26)
- Primary completion: 2023-08-31 (anticipated) (ClinicalTrials.gov record NCT04239391, source copy `cardio:ctgov-nct04239391-2021-04-21`, retrieved 2026-10-26)
- Completion: 2023-11-01 (anticipated) (ClinicalTrials.gov record NCT04239391, source copy `cardio:ctgov-nct04239391-2021-04-21`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT04239391, source copy `cardio:ctgov-nct04239391-2021-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04239391-2021-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
- Condition: End Stage Renal Disease
- Intervention (Drug): Triferic
- Lead sponsor: Rockwell Medical Technologies, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Rockwell Medical Technologies, Inc. (`cardio:org-rockwell-medical-technologies-inc`)

## Provenance

Content hash: e343c15506ef6ec76a0d6248e84d480da4a40514c0197256d7e711ffc3fa8382
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
